The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | ASCO 2026 highlights advances in targeted therapies for molecularly driven NSCLC
Alessandro Di Federico, MD, Memorial Sloan Kettering Cancer Center, New York, NY, highlights key advances in targeted therapies for non-small cell lung cancer (NSCLC) presented at the 2026 ASCO Meeting, including results from the Phase III LIBRETTO-432 trial (NCT04819100) evaluating adjuvant selpercatinib in RET fusion-positive disease, promising early data for KRAS-G12C inhibitor combinations in the frontline setting, and the seven-year update from the CROWN trial (NCT03052608) of lorlatinib in ALK-positive NSCLC. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
